Favorability *******
***** *********'* ************ *** ******** *** positive *******, **** **** **% ** respondents *** ** ******* ** *********.
********* *** ******** **** ****-***** ******* of *** *.*. *** *** ******* net *************:
Key ******
*********** *** **** ***** ********* **** largely ******** ***** *** ******* *** negative ***** *** *****, ********* *******, and ******** ** ****** ** **** response:
**** ********* ****** ***********, **** ****** of **** **** ********. **** *****/***** a ***** ***** ***** *** **** couple ** ***** ** **** ******** but ****'* ********* *** ******. ****** recognition *** ****** **** **** ******** since ** * ***** ***** ***** then **** ********* ******* *** ** market * *** ***** ***.
Most **********'* ******* ** *********
******* ******* ****$*** ******* ***** **** *** ************ ****** ***/******** ** ***** **% ** respondents *** *** **** *** ********* was:
"**** *** **** ****. *** **** known" "*******" "***´* **** *** *****" "*** ******** **** ****" "***'* *** **** ***!" "***** ***** ** **." "***** ***** ** ****" "*** ********" "** **********" '*.*." "**** ***** ***** **** ****." "** **** ***** ***** ** *********.***. With **** ***** ****, ** **** never ******** *** ** ***** *********." "**** ***** ***** ** **" ** ** ****** *** ******** ** have *** **** ***********, ** *** integrator **********, ****** *********'* ******** *** atypically ****.
Sales ******** *** ******* ******* ***-****
******* *********** ******** *** *********’* ***** operated, ******* ** *** *** ** turnover, ** ********* ******/*******.
"** **** ** ********* ******* ******* of *** **** ****** ** ******** in ***** ***** *****. ****** *********** in ******* ************** *** ** ******* elsewhere *** *** ***** ***** **/******** needs" "********* ****** *** *********** ***** **** ID *** ******** *******. ******** *** resolution *** ********* ** ******** *******. Most ******** ****** ******** ** *** meet ***** ************." "**** ******** **** ******** ******* **** end *****, *** ***** ******** ******* what **** *** ******** *******" "* *** ** *** ** **** marketing. ***** **** *** ****** ** testing" "*** **********, **** ********** ** *** sale *** *** ** ********** *************" *********
******* *********** **** ********* **** ********* was *********, ~$*,*** **** * ******* **. **** **** ******* manufacturers.
"* **** ****** ** **** ** customers ***** ** *** *** **** vs ******* ****'* *** **** **** budgets" "* **** **** *'** ****, *** the **** ***'* *********** *** *** markets * *****" "********* *** ***** ***** * ******* this ** *** ****" Positive ******** ***** **********
*********** **** ******* ******** ***** *** technology ******.
"** **** *** * *** ** success **** *** ********* ******* ****. For ****** *********** ** ** ** amazing ******* ****. ********* ******** *** the *********** ******** ** *** ***** have * *** ** **** ** do ** ***** **. * ** excited ** *** **** ** ***** new ******* ********* **** **** ***** a ****** **** *** ** * more *********** *****. *** **** ******** we **** *** *** ********* *** been *******. **** ** ** ** place ** ***** ** **** ** body ***** ** **** ***** ** in **** ** ************ *** *** of ****** ***********. ** ** *** of ***** ** *** **** **** you **** ********." "***** ********** *** ***** ********* *** some ******** *******." "**** *** ***** ** *** **** promoting ********* ** ***** ** ****** is **** ****. ******* ***** ******** there *** **** ***** ******** ****** since **** **** ******* ** ********** people *** ** *** ** ******* the ********. ******* *** **** *** very **** ******* *******, ** ****** how **** *** ****** **** ******* is **** *********" "***** ********* *** ****** ***********. **** need ****** *** ******" "***** **********" Face *********** *************
********* ***** **** *********** ***** ** controversial *** ***** ******* **********, ********** in *** *.*. *** *.*. ******* integrators ********* ********** ******* ** *** technology **** ****. ** ********, *********** has *** * ***** ****** ** **** *********** ******** ** **** ** ******. *********’* **** ****** ******* ***** ** $** ******* *** ** ***** money ** ********** **** ************ ** access ******* *** **************.
"* ** *** * *** ** facial ***********. "'** ********* ********* ******** ****** **** identifies ******* ** ******** *** ***** contact ******* ** ****-**** *** ************ while ********** *** ******** ** **********.' No ******" "***** ********** ** ********** *** ****** well ** * **** ** *** on * ******** ****. *** ***** is **** ****** **** *** ****** recognition *** ***** ****** **** *************. There ***** ** ** ***** * bit ** ******** ** ****" "***** ***** ** ******* ******* ********** is ** *********** ******* *** ***** skeptical ** ** *** **** **** fit ** **** **** ************" A *** ** ***** ***** **** ***** *******
***** ******** **** ***** ********* ****** over $** ******* ** **** **** ***** ** ************ ************ ****-*********** ******** . ******** ********* ********** **** *** *******$** ******* *********** ***** *** ** ***********. ***** ** negative ******** ***** ********* ***** ******* and ********, ***** **** ****** **% of *********** ********* “***’* ****”, ***** aggressive (*** *********) ******* **** *** delivered * ******. *******, **** ******** a *** ******** ****** ******* ******* a ************* ********** *** *********** **** largely ******** ***** *** ******* ** their **** *********** **********.
Comments (15)
Undisclosed #1
***** *******. *****.
Create New Topic
Undisclosed Integrator #2
**** ********* * **** ****, *** way **********.
Create New Topic
Undisclosed End User #3
* *** ******** **** ** ******** and ******* ******* **** ********* ******* and ******* *** *** ***** ** wanted ** ** ** ** ***** of ********. *** ** *** ***** and *** ****** ** ******** **** very **** ** **** ** *** you **** **** *** *********... ***** makes ** **** *********.
Create New Topic
MICHAEL PETROV
"******* *********** **** ********* **** ********* was *********, ~$*,*** **** * ******* vs. **** **** ******* *************." ***'* offering *** ****? * ***** **** Herta ****** *** ***** *** **** price ** *********. ** ***** ** indeed * **** ***** ******* ****** the ********** ****** **** ** **** in ***** ********* ******** ***** ***** scales **** *** ***** *** *******.
Create New Topic
MICHAEL PETROV
******* ******* **** ***** *** ********* are ******** ******* ****** **** ********* in *** **** ****** *********** ******** tests, *** * ******* **'* * different ****** ***** ***** ********* *** sanctioned ** *** ** ********** *** human ****** ******. * ***** ******* sane ** *** ***/** ***** *** a ********* ******** ****** ******** ********* PII **** ****, ****** *** ******** is **** ** ***** **********, ********* even ******* **** **** ** **** a ******!
Create New Topic
MICHAEL PETROV
***** ******* *****. *** ********* ******* inside *** ****** *** **** ** the ******* ****** *** *** ** exactly *** **** ** ****'* ****** by ****, *** *** ***** ** what *** ******* ****** ** *** be ********* **** **** *** ******* vendors **** ** **** ** ***** of ***, *** *** ***** ************ etc. *******, * ***** *** ** as *** ** ******* *** ******* products *********** ******** - **** ** us ******* *** ***** **** *** claim *********** ** *** ***** ** Uygur ********** ************, ********* ** ***** streams! *** *** ******* **, ** seems ** ** ******* ** **********...
Create New Topic
MICHAEL PETROV
****** ***** ****'* **** **** **** effectiveness ***** **** ***** ** *** level **** **** ***** **** **********. However, *** ********* ******** ** ***** convincing, ** * ****** ** ******** like *********’* **** ************ ******* **** **** 7 ******* ** ******* *** ******** – **********. *********, *********** ** * ****** is ****** ***** ** ********* ********** and ****** (**** **** ****** ** use ** ** ********* ********* ***** affiliation, *** ***********, ******** ****, **, etc.), *** ******** * ******** ****** on * ********* ** ******* **** those ******* *** ** **!
Create New Topic